A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Summary

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Interventions

• LY4170156 · DRUG

  Intravenous

• bevacizumab · DRUG

  IV

• carboplatin · DRUG

  IV

• Itraconazole · DRUG

  oral

• pembrolizumab · DRUG

  IV

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Have one of the following solid tumor cancers:

  * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
  * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
  * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC

Exclusion Criteria:

* Individual with known or suspected uncontrolled central nervous system (CNS) metastases
* Individual with history of carcinomatous meningitis
* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
* Individual with evidence of corneal keratopathy or history of corneal transplant
* Any serious unresolved toxicities from prior therapy
* Significant cardiovascular disease
* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
* History of pneumonitis/interstitial lung disease
* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

Sites (23)

• HonorHealth, Scottsdale, Arizona · RECRUITING
• University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California · RECRUITING
• South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan · RECRUITING
• NYU Langone Health - Long Island, Mineola, New York · RECRUITING
• New York University (NYU) Clinical Cancer Center, New York, New York · RECRUITING
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York · RECRUITING
• The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio · RECRUITING
• The University of Texas - MD Anderson Cancer Center, Houston, Texas · RECRUITING
• START Mountain Region, West Valley City, Utah · RECRUITING
• Cancer Research SA, Adelaide, Australia · RECRUITING
• Icon Cancer Centre South Brisbane, QLD, Australia · RECRUITING
• Centre Leon Berard, Lyon, France · RECRUITING
• Institut de Cancerologie de l'Ouest - site St-Herblain, Saint-Herblain, France · RECRUITING
• Oncopole Claudius Regaud, Toulouse, France · RECRUITING
• Humanitas San Pio X, Milan, Italy · RECRUITING
• Istituto Europeo di Oncologia, Milan, Italy · RECRUITING
• Shizuoka Cancer Center, Shizuoka, Japan · RECRUITING
• National Cancer Center Hospital, Tokyo, Japan · RECRUITING
• Cancer Institute Hospital of JFCR, Tokyo, Japan · RECRUITING
• National Cancer Center, Goyang-si Gyeonggi-do, South Korea · RECRUITING
• Hospital Universitario Vall d'Hebron, Barcelona, Spain · RECRUITING
• Hospital Universitario 12 de Octubre, Madrid, Spain · RECRUITING
• Hospital Clinico Universitario de Valencia, Valencia, Spain · RECRUITING